Brought to you by 
Lilly agrees to buy Icos for $2.1bn
12 Nov 2021
Executive Summary
Eli Lilly has entered into a definitive agreement to buy its biotech partner Icos in an all-cash deal. Lilly will pay $32 for each outstanding Icos share (a 21% premium to the 10-day pre-announcement market average), valuing the company at about $2.1bn.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly agrees to buy Icos for $2.1bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice